Pfizer Return on Investment 2010-2022 | PFE

Current and historical return on investment (ROI) values for Pfizer (PFE) over the last 10 years.
Pfizer ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-06-30 $30.76B $121.76B 26.40%
2022-03-31 $24.15B $118.34B 21.47%
2021-12-31 $19.43B $113.66B 17.84%
2021-09-30 $17.14B $112.22B 16.22%
2021-06-30 $13.45B $105.67B 12.63%
2021-03-31 $9.91B $104.21B 9.11%
2020-12-31 $8.25B $100.61B 7.63%
2020-09-30 $2.62B $115.28B 2.43%
2020-06-30 $3.13B $115.09B 3.00%
2020-03-31 $5.32B $101.62B 5.34%
2019-12-31 $6.71B $99.40B 6.85%
2019-09-30 $5.62B $101.44B 5.78%
2019-06-30 $6.43B $96.09B 6.54%
2019-03-31 $6.14B $94.89B 6.20%
2018-12-31 $5.67B $96.67B 5.62%
2018-09-30 $14.00B $105.32B 13.59%
2018-06-30 $13.90B $99.06B 13.82%
2018-03-31 $13.66B $102.37B 13.80%
2017-12-31 $13.72B $105.19B 14.12%
2017-09-30 $13.17B $95.61B 14.06%
2017-06-30 $12.53B $92.89B 13.43%
2017-03-31 $12.26B $95.08B 13.12%
2016-12-31 $12.15B $91.24B 13.13%
2016-09-30 $12.22B $94.04B 13.13%
2016-06-30 $12.56B $93.52B 13.41%
2016-03-31 $12.68B $91.17B 13.52%
2015-12-31 $11.82B $93.74B 12.42%
2015-09-30 $12.14B $96.20B 12.44%
2015-06-30 $12.46B $93.91B 12.34%
2015-03-31 $12.82B $96.96B 12.23%
2014-12-31 $13.25B $103.16B 12.38%
2014-09-30 $14.15B $109.97B 13.10%
2014-06-30 $14.45B $109.22B 13.37%
2014-03-31 $14.78B $105.72B 13.64%
2013-12-31 $15.18B $107.08B 13.74%
2013-09-30 $14.70B $110.17B 13.13%
2013-06-30 $14.46B $110.51B 12.83%
2013-03-31 $15.04B $114.31B 13.34%
2012-12-31 $15.26B $112.71B 13.45%
2012-09-30 $14.62B $113.20B 12.74%
2012-06-30 $14.96B $110.83B 12.69%
2012-03-31 $14.12B $117.22B 11.63%
2011-12-31 $13.97B $117.55B 11.31%
2011-09-30 $13.94B $125.93B 11.08%
2011-06-30 $13.62B $124.69B 10.80%
2011-03-31 $13.80B $125.84B 10.94%
2010-12-31 $13.41B $126.68B 10.59%
2010-09-30 $11.49B $127.08B 8.94%
2010-06-30 $11.85B $124.64B 9.77%
2010-03-31 $10.77B $128.36B 9.46%
2009-12-31 $10.96B $133.64B 10.72%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $245.989B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $435.655B 16.59
Eli Lilly (LLY) United States $292.179B 37.05
AbbVie (ABBV) United States $249.673B 10.61
Merck (MRK) United States $218.318B 11.40
Novo Nordisk (NVO) Denmark $215.616B 28.44
Novartis AG (NVS) Switzerland $165.082B 12.17